Physician profile
Eric S Miller
NPI 1427012780
$4,061.62
in general payments reported to CMS, 2019-2025
22 companies · $846 in 2025
The $846 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $150 · 2021: $213 · 2022: $344 · 2023: $1,528 · 2024: $576 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,841 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,840.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,278.44 | 2019-2024 | |
| Abbvie INC. | $1,093.57 | 2019-2025 | |
| Novo Nordisk INC | $250.95 | 2023-2024 | Wegovy, Rybelsus |
| Lilly USA, LLC | $230.83 | 2025 | Mounjaro, Zepbound |
| Myovant Sciences INC. | $175.91 | 2021-2022 | |
| Exact Sciences Corporation | $161.77 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $129.78 | 2024-2025 | Veozah |
| Abbott Laboratories | $103.14 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $91.56 | 2023 | Myfembree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.47 | 2024-2025 | Jardiance |
| Sage Therapeutics, LLC | $88.81 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $59.20 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.38 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $46.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.08 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $33.02 | 2025 | Zoryve |
| Therapeuticsmd, INC. | $30.65 | 2019 | |
| Dexcom, INC. | $30.57 | 2025 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $30.46 | 2019-2020 | |
| Shield Therapeutics INC | $16.30 | 2025 | |
| Meditrina | $15.08 | 2022 | |
| Covidien LP | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.